468 related articles for article (PubMed ID: 35933930)
21. [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].
Kushida T; Hirosawa M; Goto M; Seike Y; Kitamura N; Nakanishi T; Tanaka A; Higashi T; Morimoto H; Tsukada J
Rinsho Ketsueki; 2024; 65(3):180-182. PubMed ID: 38569863
[TBL] [Abstract][Full Text] [Related]
22. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
Kawasaki N; Nishito Y; Yoshimura Y; Yoshiura S
Br J Haematol; 2022 Oct; 199(2):245-255. PubMed ID: 35764309
[TBL] [Abstract][Full Text] [Related]
23. Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Kumar A; Fraz MA; Usman M; Malik SU; Ijaz A; Durer C; Durer S; Tariq MJ; Khan AY; Qureshi A; Faridi W; Nasar A; Anwer F
Curr Treat Options Oncol; 2018 Sep; 19(10):50. PubMed ID: 30173370
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Belada D; Kopeckova K; Bergua Burgues JM; Stevens D; André M; Persona EP; Pichler P; Staber PB; Trneny M; Duell J; Waldron-Lynch M; Wagner S; Mukhopadhyay A; Dirnberger-Hertweck M; Burke JM; Nowakowski GS
Blood; 2023 Oct; 142(16):1348-1358. PubMed ID: 37369099
[TBL] [Abstract][Full Text] [Related]
25. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
[TBL] [Abstract][Full Text] [Related]
27. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
[TBL] [Abstract][Full Text] [Related]
29. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Harris LJ; Patel K; Martin M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202794
[TBL] [Abstract][Full Text] [Related]
30. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
31. United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
Tarantelli C; Bertoni F
Br J Haematol; 2022 Oct; 199(2):169-170. PubMed ID: 35917107
[TBL] [Abstract][Full Text] [Related]
32. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
[TBL] [Abstract][Full Text] [Related]
34. Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatments.
Castelli R; Gidaro A; Deliliers GL; Bergamaschini L
Anticancer Drugs; 2021 Mar; 32(3):323-329. PubMed ID: 33534413
[TBL] [Abstract][Full Text] [Related]
35. Economic evaluation of polatuzumab-bendamustine-rituximab
Calamia M; McBride A; Abraham I
J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
[TBL] [Abstract][Full Text] [Related]
36. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.
Brooks TR; Caimi PF
Blood Rev; 2024 Jan; 63():101140. PubMed ID: 37949705
[TBL] [Abstract][Full Text] [Related]
37. Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
Varma G; Goldstein J; Advani RH
Hematol Oncol; 2023 Jun; 41 Suppl 1():92-106. PubMed ID: 37294966
[TBL] [Abstract][Full Text] [Related]
38. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Epperla N; Kumar A; Abutalib SA; Awan FT; Chen YB; Gopal AK; Holter-Chakrabarty J; Kekre N; Lee CJ; Lekakis L; Lin Y; Mei M; Nathan S; Nastoupil L; Oluwole O; Phillips AA; Reid E; Rezvani AR; Trotman J; Zurko J; Kharfan-Dabaja MA; Sauter CS; Perales MA; Locke FL; Carpenter PA; Hamadani M
Transplant Cell Ther; 2023 Sep; 29(9):548-555. PubMed ID: 37419325
[TBL] [Abstract][Full Text] [Related]
39. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.
Spinner MA; Advani RH
Oncology (Williston Park); 2022 Jan; 36(1):51-58. PubMed ID: 35089671
[TBL] [Abstract][Full Text] [Related]
40. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]